

Bod Science announces significant progress in Aqua Phase PK Studies and remaining Acquisition Asset Deed milestone

- Final results of Bod’s first PK assessment of the bioavailability of CBD using Aqua Phase technology compared with CBD in MCT oil in capillary blood, expected early July 2023
- Results from a Phase I PK study looking at bioavailability in venous blood are anticipated to be available by the end of July 2023
- Amendment to the date by which the final milestone (Phase I PK Studies) must be completed under Aqua Phase Acquisition Asset Purchase Deed updated to 31 July 2023. On completion, Bod’s initial acquisition consideration of GBP 1 million will be triggered

Sydney, Australia – 30 June 2023: Cannabis focused drug development and product innovation company Bod Science Limited (“Bod” or “the Company”) (ASX: BOD) is pleased to provide this update on the development of the Aqua Phase delivery technology¹ which has the potential to substantially increase the bioavailability of lipophilic (non-soluble) cannabis compounds in humans allowing more rapid onset, better efficacy and lower dosage rates. Cannabidiol (CBD) and cannabinoids intrinsically have poor biological absorption – oral CBD compounds in oil are estimated to have only 6 to 8% bioavailability. Aqua Phase uses a common compound combined with CBD under specific mechanical and heating conditions to deliver a stable, highly bioavailable compound.

Ultraviolet (UV) analysis of the solubility of Aqua Phase CBD using UV-Vis Spectrophotometry² compared with standard CBD preparations have been undertaken at a UK University, confirming that Aqua Phase CBD solubility ranges from 1.6 millimolar (mM) to 2.7mM under various conditions, whereas standard CBD solubility is 0.2 micromolar(μM). This increase in solubility (approaching 10,000 times) is remarkable. Aqueous solubility is a key rate-limiting parameter influencing biological activity and gastrointestinal absorption of a drug from solid lipophilic dosage forms. As such, solubility is one of the important and main considerations studied during the pre-formulation of any drugs’ dosage form.

Bod is currently undertaking two PK studies to demonstrate the enhanced bioavailability of CBD using Aqua Phase technology compared with CBD in MCT oil. The first PK study assessing bioavailability in capillary blood, using microsampling technology, has 10 volunteers involved. All samples have been collected from the 10 volunteers and laboratory analysis is being undertaken at present, with final results early July 2023.

The second PK study, a Phase I study investigating bioavailability in venous blood, has enrolled 12 participants, who have been dosed with either Aqua Phase CBD 100mg or CBD 100mg in oil (the sequence of administration being randomised). Participants will return to the clinic for the second dosing day in early July 2023, where they will receive the other product. Final results from the Phase I PK study via venous blood are anticipated to be completed by the end of July 2023.

Success in Bod’s PK studies will satisfy the milestone obligations under the Aqua Phase Asset Purchase Deed for Bod’s acquisition of Aqua Phase, triggering the initial acquisition consideration of GBP 1 million. This remains the only condition yet to be fulfilled under the Asset Purchase Deed and, in line with this, the Company has agreed with the Aqua Phase Inventors to amend the date by which this test must be completed to 31 July 2023, from the previously agreed 30 June 2023.

Management commentary:

CEO Ms Jo Patterson said: “Aqua Phase, as a unique delivery format promises to be a key value-driver in enabling CBD, other cannabinoids and other lipophilic compounds to be identified as first line treatments in global pharmaceutical markets.

¹ ASX Announcement – 30 August 2022: Bod to acquire Aqua Phase

² UV-Vis Spectrophotometry is a quantitative technique used to measure how much a chemical substance absorbs light. Solubility of that compound can then be calculated using an equation where $y = mx + b$ where y is absorbance, x is concentration, m the slope and b the intercept

“Bod’s acquisition of Aqua Phase has seen a number of exciting milestones to date, with final landmarks imminent, providing the baseline data to support global commercialisation, and lead to innovative and transformative delivery formats across numerous markets, including food and beverage.”

This announcement has been approved by the Board of Bod Science Limited.

-ENDS-

About Bod Science:

Bod Science (ASX:BOD) is a cannabis focused drug development and product innovation company.

Bod is focused on progressing research and development with a defined clinical trial pathway to commercialise and deliver premium, scientifically proven and trusted products for patients and consumers.

The company has a number of existing partnerships with large corporate companies and collaborations with leading research organisations to advance the use of Cannabis related medicines with therapeutic indications.

For more information please contact:

Jo Patterson
Chief Executive Officer
Info@bodaustralia.com
+61 2 9199 5018

Amalie Schreurs
White Noise Communications
amalie@whitenoisecomms.com
+61 431 636 033